ArticlemBio2016
Sequential Acquisition of Virulence and Fluoroquinolone Resistance Has Shaped the Evolution of Escherichia coli ST131.
Article in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 147 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
147 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages.Clinical microbiology reviews · 2019Pooled it
- Trial
- Genomic global epidemiology and evolution ofMicrobial genomics · 2026Article
- Mapping the evolutionary path towards multi-drug resistance in the pandemicMicrobial genomics · 2026Article
- Molecular characterization of extended-spectrum β-lactamases-producing Escherichia coli isolated from patients with bacteremia.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Genomic surveillance reveals long-term endemicity and outbreak potential ofMicrobial genomics · 2026Article
- Community-associated quinolone-resistant and extended-spectrum beta-lactamase-producingmSystems · 2026Article
- Emergence and regional spread of extended-spectrum β-lactamase-producingMicrobiology spectrum · 2026Article
- Fluoroquinolone Resistance Patterns in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Machine learning-based lineage prediction from antimicrobial susceptibility testing phenotypes forMicrobial genomics · 2026Article
- Origin and development of twoMicrobial genomics · 2025Article
- The First Isolation of Multiple Antifungal-Drug-Resistant Trichophyton Rubrum in China and the Novel Resistance Mechanism.Mycoses · 2025Article
- Draft genome of an extended-spectrum β-lactamase-producing multidrug-resistantMicrobiology resource announcements · 2025Article
- Emergence of a carbapenem-resistant atypical uropathogenic Escherichia coli clone as an increasing cause of urinary tract infection.Nature communications · 2025Article
- Molecular Epidemiology and Clinical Characterization of Carbapenemase-Producing Enterobacter Species From an International Cohort.The Journal of infectious diseases · 2025Observational
- Genetic Evolution of Antibiotic Resistance and Virulence Genes inMicroorganisms · 2025Article
- A First Report on Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Quantifying the Evolutionary Dynamics of Structure and Content in Closely Related E. coli Genomes.Molecular biology and evolution · 2025Article
- Predicting sepsis mortality into an era of pandrug-resistant E. coli through modeling.Communications medicine · 2024Article
- Article
87 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledEscherichia coli ST131 is the most frequently isolated fluoroquinolone-resistant (FQR) E. coli clone worldwide and a major cause of urinary tract and bloodstream infections. Although originally identified through its association with the CTX-M-15 extended-spectrum β-lactamase resistance gene, global genomic epidemiology studies have failed to resolve the geographical and temporal origin of the ST131 ancestor. Here, we developed a framework for the reanalysis of publically available genomes from different countries and used this data set to reconstruct the evolutionary steps that led to the emergence of FQR ST131. Using Bayesian estimation, we show that point mutations in chromosomal genes that confer FQR coincide with the first clinical use of fluoroquinolone in 1986 and illustrate the impact of this pivotal event on the rapid population expansion of ST131 worldwide from an apparent origin in North America. Furthermore, we identify virulence factor acquisition events that predate the development of FQR, suggesting that the gain of virulence-associated genes followed by the tandem development of antibiotic resistance primed the successful global dissemination of ST131. IMPORTANCE: Escherichia coli sequence type 131 (ST131) is a recently emerged and globally disseminated multidrug-resistant clone frequently associated with human urinary tract and bloodstream infections. In this study, we have used two large publically available genomic data sets to define a number of critical steps in the evolution of this important pathogen. We show that resistance to fluoroquinolones, a class of broad-spectrum antibiotic used extensively in human medicine and veterinary practice, developed in ST131 soon after the introduction of these antibiotics in the United States, most likely in North America. We also mapped the acquisition of several fitness and virulence determinants by ST131 and demonstrate these events occurred prior to the development of fluoroquinolone resistance. Thus, ST131 has emerged by stealth, first acquiring genes associated with an increased capacity to cause human infection, and then gaining a resistance armory that has driven its massive population expansion across the globe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.